Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Paxlovid by Quarter
Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide operational (constant-currency) YoY (%) (%)
Pfizer Paxlovid: -95.0% in Q2 2026, down 166.0 pts from a year earlier.
Latest, Q2 2026
-95.0%
Period ended Jun 28, 2026
Change on a year earlier
-166.0 pts
71.0% in Q2 2025
History
10 quarters
Since Q2 2023
Sources
10
Documents cited below
Where the Q2 2026 figure comes from
“|| Paxlovid | 21 | 427 | (95%) | (95%) | — | 328 | (100%) | 20 | 99 | (80%) | (81%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Paxlovid (%), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/paxlovid-oper-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.